Gnana P Krishnamoorthy
Overview
Explore the profile of Gnana P Krishnamoorthy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
754
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krishnamoorthy G, Glover A, Untch B, Sigcha-Coello N, Xu B, Vukel D, et al.
J Exp Med
. 2025 Feb;
222(5).
PMID: 39992626
RBM10 modulates transcriptome-wide cassette exon splicing. Loss-of-function RBM10 mutations are enriched in thyroid cancers with distant metastases. Analysis of transcriptomes and genes mis-spliced by RBM10 loss showed pro-migratory and RHO/RAC...
2.
Li L, Jiang W, Wei W, Krishnamoorthy G, Hu P, Chen M, et al.
Sci Data
. 2024 Dec;
11(1):1448.
PMID: 39732735
Thyroid nodules are a common endocrine condition with an increasing incidence over the decades. Data-independent acquisition has been widely utilized in discovery proteomics to identify disease biomarkers and therapeutic targets....
3.
Tiedje V, Vela P, Yang J, Untch B, Boucai L, Stonestrom A, et al.
bioRxiv
. 2024 Oct;
PMID: 39415999
Anaplastic thyroid cancer (ATC) is a clinically aggressive malignancy with a dismal prognosis. Combined BRAF/MEK inhibition offers significant therapeutic benefit in patients with -mutant ATCs. However, relapses are common and...
4.
Nigam A, Krishnamoorthy G, Chatila W, Berman K, Saqcena M, Walch H, et al.
Oncogene
. 2024 Aug;
43(37):2806-2819.
PMID: 39152269
In the clinical development of farnesyltransferase inhibitors (FTIs) for HRAS-mutant tumors, responses varied by cancer type. Co-occurring mutations may affect responses. We aimed to uncover cooperative genetic events specific to...
5.
Krishnamoorthy G, Glover A, Untch B, Sigcha-Coello N, Xu B, Vukel D, et al.
bioRxiv
. 2024 Jul;
PMID: 39026820
RBM10 modulates transcriptome-wide cassette exon splicing. Loss-of-function mutations are enriched in thyroid cancers with distant metastases. Analysis of transcriptomes and genes mis-spliced by RBM10 loss showed pro-migratory and RHO/RAC signaling...
6.
Landa I, Thornton C, Xu B, Haase J, Krishnamoorthy G, Hao J, et al.
Mol Cancer Res
. 2023 Jul;
21(11):1163-1175.
PMID: 37478162
Implications: Telomerase-driven cancer progression activates pathways that can be dissected and perhaps therapeutically exploited.
7.
Fagin J, Krishnamoorthy G, Landa I
Nat Rev Cancer
. 2023 Jul;
23(9):631-650.
PMID: 37438605
The genomic simplicity of differentiated cancers derived from thyroid follicular cells offers unique insights into how oncogenic drivers impact tumour phenotype. Essentially, the main oncoproteins in thyroid cancer activate nodes...
8.
Boucai L, Saqcena M, Kuo F, Grewal R, Socci N, Knauf J, et al.
Clin Cancer Res
. 2023 Feb;
29(8):1620-1630.
PMID: 36780190
Purpose: The determinants of response or resistance to radioiodine (RAI) are unknown. We aimed to identify genomic and transcriptomic factors associated with structural responses to RAI treatment of metastatic thyroid...
9.
Landa I, Thornton C, Xu B, Haase J, Krishnamoorthy G, Hao J, et al.
bioRxiv
. 2023 Feb;
PMID: 36747657
Mutations in the promoter of the telomerase reverse transcriptase ( ) gene are the paradigm of a cross-cancer alteration in a non-coding region. promoter mutations (TPMs) are biomarkers of poor...
10.
Boucai L, Salas-Lucia F, Krishnamoorthy G, Sherman E, Rudin C, Drilon A, et al.
JCO Precis Oncol
. 2022 Jun;
6:e2100496.
PMID: 35704797
Purpose: The development of the selective RET inhibitors selpercatinib and pralsetinib has revolutionized the treatment of metastatic progressive RET-mutant medullary thyroid carcinoma (MTC) and other RET-driven cancers, given their more...